Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696/Amlodipine combination in hypertension
NCT06236061Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amlodipine in hypertension (HTN) (5 arms), sponsored by Novartis. Primary endpoint: Mean Sitting Systolic Blood Pressure at 8 weeks. Started Apr 2024; status: completed.
02
Drugs
amlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06236061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236061.